New combo aims to stop postpartum bleeding in bleeding disorder
NCT ID NCT04344860
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 3 trial tested whether adding tranexamic acid to recombinant von Willebrand factor (rVWF) reduces postpartum hemorrhage better than rVWF alone in 20 pregnant women with von Willebrand disease. Participants received either the combination or rVWF alone at delivery. The main goal was to measure blood loss during and after childbirth. This study aims to improve bleeding control in a high-risk group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Recombinant von Willebrand factor (rVWF) and tranexamic acid
What this could lead to
If it works, this combination could offer a better way to prevent dangerous bleeding after childbirth in women with von Willebrand disease.
What could go wrong
This is a small, single-center trial with only 20 participants, so results may not apply to everyone. The added benefit of tranexamic acid over rVWF alone is uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTPARTUM HEMORRHAGE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hemophilia Center of Western PA
Pittsburgh, Pennsylvania, 15213, United States